A carregar...
Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer
HER2-positive breast cancer correlates with more aggressive tumor growth, a poorer prognosis and reduced overall survival. Currently, trastuzumab (Herceptin), which is an anti-HER2 antibody, is one of the key drugs. There is evidence indicating that conjugation of trastuzumab with chemotherapy drugs...
Na minha lista:
| Publicado no: | Drug Deliv |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6058718/ https://ncbi.nlm.nih.gov/pubmed/29405790 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10717544.2018.1435746 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|